Shares of G1 Therapeutics Inc (NASDAQ:GTHX) have been assigned an average recommendation of “Buy” from the eight analysts that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price target among brokers that have covered the stock in the last year is $52.00.
GTHX has been the subject of several research analyst reports. ValuEngine raised G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Cowen reaffirmed a “buy” rating on shares of G1 Therapeutics in a report on Monday, March 5th. BTIG Research reaffirmed a “buy” rating and set a $48.00 target price on shares of G1 Therapeutics in a report on Wednesday, March 7th. Needham & Company LLC upped their target price on G1 Therapeutics from $42.00 to $60.00 and gave the company a “buy” rating in a report on Friday, May 18th. Finally, HC Wainwright assumed coverage on G1 Therapeutics in a report on Tuesday, May 29th. They set a “buy” rating and a $61.00 target price for the company.
G1 Therapeutics traded up $1.95, hitting $46.78, during midday trading on Tuesday, MarketBeat.com reports. The stock had a trading volume of 1,951,182 shares, compared to its average volume of 344,212. The firm has a market cap of $1.53 billion and a P/E ratio of -13.10. G1 Therapeutics has a 12 month low of $12.04 and a 12 month high of $52.76.
G1 Therapeutics (NASDAQ:GTHX) last announced its quarterly earnings data on Thursday, May 3rd. The company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by ($0.07). equities analysts anticipate that G1 Therapeutics will post -2.75 EPS for the current year.
In other news, insider Mark A. Velleca sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, April 16th. The stock was sold at an average price of $36.00, for a total transaction of $270,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Clay Thorp sold 37,500 shares of the business’s stock in a transaction that occurred on Wednesday, May 23rd. The stock was sold at an average price of $51.11, for a total value of $1,916,625.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 854,750 shares of company stock valued at $41,024,655. Insiders own 15.92% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Franklin Resources Inc. boosted its position in shares of G1 Therapeutics by 10.1% during the fourth quarter. Franklin Resources Inc. now owns 1,535,616 shares of the company’s stock worth $30,467,000 after buying an additional 141,000 shares during the period. BlackRock Inc. lifted its position in G1 Therapeutics by 71.9% in the first quarter. BlackRock Inc. now owns 1,281,060 shares of the company’s stock worth $47,463,000 after purchasing an additional 535,615 shares during the period. Rock Springs Capital Management LP lifted its position in G1 Therapeutics by 33.8% in the first quarter. Rock Springs Capital Management LP now owns 287,000 shares of the company’s stock worth $10,633,000 after purchasing an additional 72,500 shares during the period. Point72 Asset Management L.P. lifted its position in G1 Therapeutics by 12.0% in the first quarter. Point72 Asset Management L.P. now owns 224,000 shares of the company’s stock worth $8,299,000 after purchasing an additional 24,000 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in G1 Therapeutics by 1,313.5% in the first quarter. JPMorgan Chase & Co. now owns 221,555 shares of the company’s stock worth $8,209,000 after purchasing an additional 205,881 shares during the period. Institutional investors and hedge funds own 61.25% of the company’s stock.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.